Claims for Patent: 11,708,333

Summary for Patent: 11,708,333

Title:	Human plasma kallikrein inhibitors
Abstract:	Disclosed are compounds of formula I:
Inventor(s):	Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
Assignee:	Biocryst Pharmaceuticals Inc
Application Number:	US17/543,929
Patent Claims:	1. A method of treating or preventing angioedema, comprising orally administering to a subject in need thereof an oral dosage form comprising a therapeutically effective amount of a compound having the structure: wherein the compound is a bis(hydrochloride salt); and wherein the stereochemical configuration at any chiral center is R, S, or a mixture of R and S. 2. The method of claim 1, wherein the oral dosage form is administered once per day. 3. The method of claim 1, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day. 4. The method of claim 1, wherein the angioedema is hereditary angioedema. 5. The method of claim 4, wherein the oral dosage form is administered once per day. 6. The method of claim 4, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day. 7. The method of claim 4, wherein the hereditary angioedema is type II hereditary angioedema. 8. The method of claim 7, wherein the oral dosage form is administered once per day. 9. The method of claim 7, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day. 10. The method of claim 1, wherein the compound is the (+)-enantiomer. 11. The method of claim 10, wherein the angioedema is hereditary angioedema. 12. The method of claim 10, wherein the oral dosage form is administered once per day. 13. The method of claim 10, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day. 14. The method of claim 11, wherein the hereditary angioedema is type II hereditary angioedema. 15. The method of claim 14, wherein the oral dosage form is administered once per day. 16. The method of claim 14, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day. 17. The method of claim 1, wherein the compound is the (−)-enantiomer. 18. The method of claim 17, wherein the angioedema is hereditary angioedema. 19. The method of claim 17, wherein the oral dosage form is administered once per day. 20. The method of claim 17, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day. 21. The method of claim 18, wherein the hereditary angioedema is type II hereditary angioedema. 22. The method of claim 21, wherein the oral dosage form is administered once per day. 23. The method of claim 21, wherein the oral dosage form is a capsule, and the oral dosage form is administered once per day.